HIF prolyl hydroxylase (HIF-PH1/2/3)

Assets acting on this target.

Class
HIF prolyl hydroxylase inhibitor (HIF-PHI)
Pathway
Hypoxia-inducible factor (HIF) / erythropoietin pathway

HIF prolyl hydroxylases (PHD1, PHD2, PHD3) are enzymes that use molecular oxygen to modify hypoxia-inducible factor (HIF), a transcription factor that governs cellular adaptation to low oxygen. Under normal oxygen levels, these enzymes hydroxylate HIF-alpha subunits, marking them for rapid degradation. When oxygen is scarce, hydroxylation slows, HIF accumulates, and it activates genes involved in oxygen delivery and metabolism, including erythropoietin (EPO), the hormone that stimulates red blood cell production, along with genes governing iron handling and blood vessel formation. HIF-PH inhibitors act as pharmacological mimics of hypoxia: by blocking the hydroxylase active site, they stabilize HIF even when oxygen is plentiful, prompting the body to increase endogenous EPO production and improve iron availability for red cell formation. This mechanism is exploited primarily in anemia associated with chronic kidney disease, where diseased kidneys produce insufficient EPO. Because the approach works upstream of EPO itself, promoting a more physiological hormone response rather than delivering a fixed exogenous dose, it represents an alternative to injectable erythropoiesis-stimulating agents. The broader HIF pathway also touches metabolism, vascular biology, and cellular stress responses, so modulation carries effects that extend beyond erythropoiesis alone.

By indication

Related mechanisms

HIF prolyl hydroxylase (HIF-PH1/2/3) drugs compared

7 drugs, stage by indication
7 drugs acting on HIF prolyl hydroxylase (HIF-PH1/2/3): developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
VadadustatVafseoAkebia Therapeutics, Medice, Tanabe Pharma Corporationsmall moleculeApprovedApproved in Chronic Kidney Disease
AND017Kind Pharmaceuticalssmall moleculePhase 3Phase 3 in Chronic Kidney Disease; Phase 2 in Myelodysplastic Syndromes
DesidustatOxemiaChina Medical System, Zydus Lifesciencessmall moleculePhase 3Phase 3 in Chronic Kidney Disease
EnarodustatJW Pharmaceutical, Shenzhen Salubris Pharmaceuticals, Shionogismall moleculePhase 3Phase 3 in Chronic Kidney Disease
MolidustatBayersmall moleculePhase 3Phase 3 in Chronic Kidney Disease
RoxadustatEvrenzoAstellas Pharma, AstraZeneca, Kyntra Biosmall moleculePhase 3Phase 3 in Chronic Kidney Disease; Phase 3 in Myelodysplastic Syndromes
SSS17Shenyang Sunshine Pharmaceuticalsmall moleculePhase 2Phase 2 in Chronic Kidney Disease

← all mechanisms